Novo Nordisk (NYSE: NVO) Misses Q2 Profit Estimates, Updates 2024 Sales and Profit Outlooks
LONDON – On Wednesday, Novo Nordisk (NYSE: NVO) posted second-quarter operating profit below expectations, raised its 2024 sales forecast but […]
NYSE: NVO
Diabetes Patients Voice Concerns as Novo Nordisk (NYSE: NVO) Moves to Scrap an Insulin Product
LONDON/WASHINGTON – Novo Nordisk’s (NYSE: NVO) decision to stop selling its long-acting insulin Levemir in the United States has left
Roche to Fast-track Anti-Obesity Drug Development to Compete with Rivals: FT Report
Swiss drugmaker Roche plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly (NYSE: LLY)
Roche to Fast-track Anti-Obesity Drug Development to Compete with Rivals: FT Report Read More »
US FDA Warns About Dosing Risks with Compounded Versions of Novo’s Weight-Loss Drug
On Friday, the U.S. Food and Drug Administration warned patients and doctors about dosing errors associated with compounded versions of
US FDA Warns About Dosing Risks with Compounded Versions of Novo’s Weight-Loss Drug Read More »
Novo Nordisk (NYSE: NVO) Faces Setback as Dutch Agency Snubs Wegovy Insurance Recommendation
AMSTERDAM/COPENHAGEN – Danish drugmaker Novo Nordisk (NYSE: NVO) said on Wednesday it was disappointed with the recommendation to the Netherlands
Novo Holdings (NYSE: NVO) Leads $100M Funding Round for Swiss Biotech Asceneuron
LONDON – Swiss biotech company Asceneuron said on Tuesday it had raised $100 million from investors including the controlling shareholder
Novo Holdings (NYSE: NVO) Leads $100M Funding Round for Swiss Biotech Asceneuron Read More »
Novo Nordisk (NYSE: NVO) Under Pressure as Sanders Calls for Price Cuts on Ozempic, Wegovy
WASHINGTON – Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk (NYSE: NVO) can be convinced to cut the
Exclusive-Most Patients Stop Using Wegovy, Ozempic for Weight Loss Within Two Years, Analysis Finds
Only one in four U.S. patients prescribed Novo Nordisk’s (NYSE: NVO) Wegovy or Ozempic for weight loss were still taking
Novo Nordisk (NYSE: NVO) Stock Dips as Rivalry Heats Up: Lilly Drug Outperforms in Weight Loss Study
LONDON – Shares in Novo Nordisk (NYSE: NVO), maker of the wildly popular obesity drug Wegovy, were down 1.1% on
